InterKrin raises $18.5M for continued work on diabetes drug
Palo Alto, Calif.-based InterKrin is developing an anti-diabetes drug. It has raised an $18.5 million in a not-yet-closed third round of funding, according to VentureWire. The round was led by Amgen and Skyline Ventures and joined by existing backers Sofinnova Ventures, OrbiMed Advisors, Asset Management, Sears Capital Management and Vivo Ventures.
Next Story: Got iBugs? Get your iPhone 2.0.1 software now
Previous Story: Tabula Digita raises round for educational games
About the Author, Eric Eldon
Eric wrote about digital media for VentureBeat until August 2009. To reach VentureBeat's current writers, email tips@venturebeat.com.
